Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment [Seeking Alpha]
Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
Last aurinia pharmaceuticals inc - common shares earnings: 3/5 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.auriniapharma.com
Company Research
Source: Seeking Alpha
1.62K Follower s Follow Play 14min Summary Aurinia Pharmaceuticals' LUPKYNIS, an FDA-approved treatment for lupus nephritis, is well-positioned to become a new standard of care due to its dual role in immunosuppression and kidney protection. The partnership with Otsuka Pharmaceutical supports Aurinia's international expansion into European and Asian markets. AUR200, now in Phase 1 trials, could be a significant future value driver targeting autoimmune diseases. Aurinia has strong financials with ample resources, positive cash flow, and trades at a compelling valuation. Although AUPH is highly dependent on LUPKYNIS, the company's growth prospects justify a "strong-buy" rating for investors aware of market adoption risks. Maks_Lab Aurinia Pharmaceuticals Inc. ( NASDAQ: AUPH ) is a biopharmaceutical company focused on autoimmune diseases. Currently, AUPH's hit product is LUPKYNIS, which is indicated for managing lupus nephritis [LN]. LN is a complication of systemi
Show less
Read more
Impact Snapshot
Event Time:
AUPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUPH alerts
High impacting Aurinia Pharmaceuticals Inc - Common Shares news events
Weekly update
A roundup of the hottest topics
AUPH
News
- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability [Yahoo! Finance]Yahoo! Finance
- Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus NephritisBusiness Wire
- Aurinia Pharmaceuticals: This Recovery Can Continue [Seeking Alpha]Seeking Alpha
- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $10.00 price target on the stock.MarketBeat
- Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare ConferenceBusiness Wire
AUPH
Earnings
- 8/1/24 - In-Line
AUPH
Sec Filings
- 9/23/24 - Form 3
- 9/20/24 - Form 4
- 9/12/24 - Form SC
- AUPH's page on the SEC website